Alcon Acquires Ivantis, Inc.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

Alcon Acquires Aerie Pharmaceuticals

August 22, 2022

Pharmaceuticals

Swiss eye-care leader Alcon has acquired Aerie Pharmaceuticals, a Durham, North Carolina-based ophthalmic pharmaceutical company, adding commercial products Rocklatan and Rhopressa as well as a clinical-stage pipeline including AR-15512. The acquisition strengthens Alcon's ophthalmic pharmaceutical capabilities and R&D expertise and is intended to expand distribution and accelerate development of Aerie's portfolio.

Alcon Acquires Majority Interest in Aurion Biotech, Inc.

March 26, 2025

Biotechnology

Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.

AbbVie Enters Strategic Alliance with iSTAR Medical for MINIject with Option to Acquire

July 20, 2022

Medical Devices

AbbVie has entered into a strategic alliance with iSTAR Medical to further develop and commercialize the MINIject minimally invasive glaucoma surgery (MIGS) device. iSTAR will receive a $60M non-dilutive upfront payment and AbbVie holds an exclusive right to acquire iSTAR, with up to $475M of additional contingent payments tied to closing and milestones; iSTAR will remain independent until completion of its STAR‑V study.

Altaris Capital Partners Acquires Intricon Corporation

May 24, 2022

Medical Devices

Altaris Capital Partners completed the acquisition of Intricon Corporation, taking the NASDAQ-listed micromedical contract developer and manufacturer private for $24.25 per share (approximately $241 million fully diluted). The deal will support Intricon’s continued development and scaling of miniature and micromedical components, sub-assemblies and devices for OEM customers across multiple production facilities in the United States and Asia.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.